The Xpert Omni platform will launch in 2016 running Cepheid test cartridges on a compact battery-operated device that is anticipated to cost less than $3,000.
The first tranche of the targeted $20 million financing round will be used to accelerate adoption of the company's melanoma test.
The developers of the method are now using the ddPCR approach to create and test assays for early colon cancer detection.
The firm saw 24 percent growth in commercial clinical reagents revenues, while clinical systems revenue was down 23 percent.
Meridian's Diagnostics segment grew 2 percent lifted by a 10 percent increase in revenues from the illumigene molecular product line.
In PLOS this week: locus linked to non-syndromic hearing loss, phylogenetic relationships of Klebsiella pneumoniae isolates, and more.
In a column at Nature, researcher Fyodor Kondrashov worries about the influence of politics on Russian science.
The term 'epigenetics' is being used by quacks to give them a veneer of science, writes Adam Rutherford at the Observer.
The NIH has issued a preliminary guidance for newborn dried blood spot research.